Gerald L. Andriole, Jr., MD, presented “What Role Do Markers Play in Establishing Active Surveillance or Definitive Care?” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.

How to cite: Andriole, Gerald L. What Role Do Markers Play in Establishing Active Surveillance or Definitive Care?” January 23rd, 2020. Accessed Dec 2021. http://rusty.grandroundsinurology.com/what-role-do-markers-play-in-establishing-active-surveillance-or-definitive-care/

What Role Do Markers Play in Establishing Active Surveillance or Definitive Care? – Summary:

Gerald L. Andriole, Jr., MD, explains that while active surveillance is on the rise, doctors can do a better job of selecting patients for it. He points out that NCCN and ASCO guidelines indicate that routine ordering of molecular biomarker tests is not recommended, and state that doctors should only perform active surveillance on low- and favorable-risk patients. He concludes that clinical criteria are very useful in determining when to use active surveillance, and notes that MRI and gene expression classifiers add some certainty to the decision. There are other markers that may aid in decision making, but the current data are sparse.

About The 30th Annual International Prostate Cancer Update:

The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Andriole delivered this educational activity during the 30th iteration of the meeting in January 2020.

For further educational activities from this conference, visit our collection page.